Business
Mercy Places First Commercial Eversense 365: The World's First and Only 365-Day Continuous Glucose Monitor
Senseonics' Eversense 365 is approved in the US as an integrated continuous glucose monitoring (iCGM) system for people with Type 1 and Type 2 diabetes aged
About this update from Senseonics Holdings, Inc.
[{"type":"text","content":"Senseonics' Eversense 365 is approved in the US as an integrated continuous glucose monitoring (iCGM) system for people with Type 1 and Type 2 diabetes aged 18 and older\nCommercial launch by Ascensia Diabetes Care underway with a new campaign to highlight the unique benefits of having just one CGM for one full year \nGERMANTOWN, Md. and ST. LOUIS, Oct. 10, 2024 /PRNewswire/ -- Senseonics Holdings, Inc. (NYSE American: SENS) (\"Senseonics\" or the \"Company\"), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, and Mercy, a leading healthcare system, today announced that the first commercial patient received the next-generation Eversense® 365 CGM system. This milestone, part of the company's previously announced collaboration with Mercy, marks the world's first commercial use of Eversense 365, the only CGM to provide one-year of accurate monitoring with minimal interruptions.\n\n \n \n \n \n \n \n\n \n\"This is a pivotal moment for people with diabetes...\"This patient and those who follow, along with their doctors, will be able to monitor glucose levels and trends for a full year, with no requirement for additional sensor replacements and only one calibration per week. Eversense 365 offers patients a truly differentiated CGM experience, enabling confident decisions, long-term peace of mind and enhanced quality of life with just one CGM. It also helps people to overcome common frustrations and interruptions experienced with traditional, short-term CGMs that are indicated to last just 10-14 days. Senseonics and Mercy expect this significant breakthrough in diabetes technology and management to improve gylcemic control for patients, reduce distress associated with managing diabetes and lower overall healthcare costs for providers and payers.\n\"Without the technology, patients deal with constant finger pricks to test their glucose or have sensors that need to be replaced every few days,\" said Dr. Jeff Ciaramita, Mercy's president of specialty service lines. \"This is a pivotal moment for people with diabetes because this groundbreaking technology allows patients a more convenient and reliable way to manage their condition for an entire year with a single sensor. As Mercy strives to make care easy for our patients...